Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference

被引:47
作者
Coleman, Robert E. [1 ]
Guise, Theresa A. [3 ]
Lipton, Allan [4 ]
Roodman, G. David [5 ]
Berenson, James R. [6 ]
Body, Jean-Jacques [7 ]
Boyce, Brendan F. [8 ]
Calvi, Laura M. [8 ]
Hadji, Peyman [9 ]
McCloskey, Eugene V. [2 ]
Saad, Fred [10 ]
Smith, Matthew R. [11 ]
Suva, Larry J. [12 ]
Taichman, Russell S. [13 ]
Vessella, Robert L. [14 ]
Weilbaecher, Katherine N. [15 ]
机构
[1] Univ Sheffield, Canc Res Ctr, Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield S10 2SJ, S Yorkshire, England
[2] Univ Sheffield, Metab Bone Ctr, Sheffield S10 2SJ, S Yorkshire, England
[3] Univ Virginia, Dept Internal Med, Div Endocrinol, Charlottesville, VA USA
[4] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Med & Oncol, Hershey, PA 17033 USA
[5] Vet Adm Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA
[6] Inst Myeloma & Bone Canc Res, West Hollywood, CA USA
[7] Univ Libre Bruxelles, CHU Brugmann, Brussels, Belgium
[8] Univ Rochester, Sch Med & Dent, Div Endocrinol Metab, New York, NY USA
[9] Univ Hosp Giessen & Marburg GmbH, Dept Endocrinol, Marburg, Germany
[10] Univ Montreal, Hop Notre Dame, Ctr Hosp, Dept Urol Oncol, Montreal, PQ, Canada
[11] Massachusetts Gen Hosp, Ctr Canc, Dept Genitourinary Med Oncol, Boston, MA USA
[12] Univ Arkansas Med Sci, Ctr Orthopaed Res, Little Rock, AR 72205 USA
[13] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA
[14] Univ Washington, Seattle, WA 98195 USA
[15] Washington Univ, Sch Med, Div Mol Oncol, St Louis, MO USA
关键词
D O I
10.1158/1078-0432.CCR-08-1572
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer. Experimental Design: A multidisciplinary consensus conference was convened to review recent progress in basic and clinical research, assess critical gaps in current knowledge, and prioritize recommendations to advance research in the next 5 years. The program addressed three principal topics: biology of metastasis, preserving normal bone health, and optimizing bone-targeted therapies. Results: A variety of specific recommendations were identified as important to advance research and clinical care over the next 5 years. Conclusions: Priorities for research in bone biology include characterizing components of the stem cell niche in bone, developing oncogenic immunocompetent animal models of bone metastasis, and investigating the unique contribution of the bone microenvironment to tumor growth and dormancy. Priorities for research in preserving normal bone health include developing methods to measure and characterize disseminating tumor cells, assessing outcomes from the major prevention trials currently in progress, and improving methodologies to assess risks and benefits of treatment. Priorities for optimizing bone-targeted therapies include advancing studies of serum proteomics and genomics to reliably identify patients who will develop bone metastases, enhancing imaging for early detection of bone metastases and early response evaluation, and developing new tests to evaluate response to bone-directed treatments.
引用
收藏
页码:6387 / 6395
页数:9
相关论文
共 51 条
[1]
[Anonymous], J CLIN ONCOLOGY S18
[2]
Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients [J].
Bellahcène, A ;
Van Riet, I ;
de Greef, C ;
Antoine, N ;
Young, MF ;
Van Camp, B ;
Castronovo, V .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (04) :1118-1121
[3]
Marked improvement in bone mineral density (BMD) for patients (pts) with monoclonal gammopathy of undetermined significance (MGUS) using zoledronic acid (ZOL) [J].
Berenson, J. R. ;
Yellin, O. ;
Boccia, R. V. ;
Flam, M. S. ;
Wong, S. ;
Batuman, O. ;
Moezi, M. M. ;
Woytowitz, D. V., Jr. ;
Duvivier, H. L. ;
Nassir, Y. ;
Swift, R. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[4]
A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer [J].
Body, JJ ;
Facon, T ;
Coleman, RE ;
Lipton, A ;
Geurs, F ;
Fan, M ;
Holloway, D ;
Peterson, MC ;
Bekker, P .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1221-1228
[5]
A pooled analysis of bone marrow micrometastasis in breast cancer [J].
Braun, S ;
Vogl, FD ;
Naume, B ;
Janni, W ;
Osborne, MP ;
Coombes, RC ;
Schlimok, G ;
Diel, IJ ;
Gerber, B ;
Gebauer, G ;
Pierga, JY ;
Marth, C ;
Oruzio, D ;
Wiedswang, G ;
Solomayer, EF ;
Kundt, G ;
Strobl, B ;
Fehm, T ;
Wong, GYC ;
Bliss, J ;
Vincent-Salomon, A ;
Pantel, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (08) :793-802
[6]
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors [J].
Brown, JE ;
Cook, RJ ;
Major, P ;
Lipton, A ;
Saad, F ;
Smith, M ;
Lee, KA ;
Zheng, M ;
Hei, YJ ;
Coleman, RE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01) :59-69
[7]
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole [J].
Bundred, Nigel J. ;
Campbell, Ian D. ;
Davidson, Neville ;
DeBoer, Richard H. ;
Eidtmann, Holger ;
Monnier, Alain ;
Neven, Patrick ;
von Minckwitz, Gunter ;
Miller, Joel C. ;
Schenk, Nora L. ;
Coleman, Robert E. .
CANCER, 2008, 112 (05) :1001-1010
[8]
Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone [J].
Clines, GA ;
Guise, TA .
ENDOCRINE-RELATED CANCER, 2005, 12 (03) :549-583
[9]
THE CLINICAL COURSE OF BONE METASTASES FROM BREAST-CANCER [J].
COLEMAN, RE ;
RUBENS, RD .
BRITISH JOURNAL OF CANCER, 1987, 55 (01) :61-66
[10]
Emerging strategies in bone health management for the adjuvant patient [J].
Coleman, Robert E. .
SEMINARS IN ONCOLOGY, 2007, 34 (06) :S11-S16